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Introduction
As of today, influenza A virus infection is very much ahealth issue for the human population. Over a 100 years
have passed since the 1918 influenza pandemic that caused
the deaths of tens of millions of people over the world, but
despite this we have not been able to develop an efficient
vaccine that can protect the population. Since they first be-
came available, >60 years ago, commercial vaccines all pri-
marily induce an antibody response targeting the surface
glycoproteins hemagglutinin (HA) and neuraminidase (NA).
The vaccine is the most effective method of protecting the
population against influenza infection available today, nev-
ertheless the U.S. Centers for Disease Control and Preven-
tion estimated the efficiency to be ranging between 20% and
60% over the last years (12,33,40,48,60). The major un-
derlying reason for this is the ever-evolving influenza A
virus. Genetic drift results in changes of the surface proteins,
making it impossible for antibodies to recognize and neu-
tralize newly evolved virus. As a result, there is an annual
need for re-evaluation and possibly re-formulation of the
vaccine in an attempt to match the circulating strains. An
alternative to the antibody-mediated immunity, targeting the
variable HA and NA, is to induce cellular immunity tar-
geting the highly conserved internal influenza proteins.
Nineteen years ago from Peter C. Doherty’s laboratory,
Christensen et al. published a study illustrating the capacity
and critical role of CD8 T cells in heterosubtypic protection,
an article that has become one of the cornerstones when
discussing the important role of CD8 T cells in cross pro-
tection against respiratory viruses (8). The data presented in
that article clearly demonstrated that by generating a large
number of influenza-specific CD8 T cells, protection against
influenza A challenge was improved, not only against
homosubtypic strains, but also against heterosubtypic influ-
enza strains where seroimmunity was lacking. Specifically,
the T cell immune response was boosted by re-infection with
serologically different influenza strains that shared the same
CD8 T cell nucleoprotein (NP) epitope. When an influenza-
specific CD8 T cell population was present before challenge,
limited expansion of the CD8 T cell population was re-
quired, thus not only protecting against the virus infection
but also limiting immunopathology. The article also illus-
trated that pre-existing cellular immunity have limitations.
Despite high numbers of cross-reactive CD8 T cells, present
as early as 1-day postchallenge, viral titers did not differ
from groups with no T cell immunity. This pinpointed an-
other important fact, the CD8 T cell response will first be
activated after the influenza virus has infected its host. Since
this publication in 2000, substantial effort has been put into
understanding the basic foundations necessary for design-
ing a vaccine generating a long-lasting cross-protective CD8
T cell population.
Memory CD8 T Cells
At the time point of the Christensen’s article, memory
T cells were considered to fall into two main categories,
central memory or effector memory T cells. Central memory
T cells, TCM, are located in the secondary lymphoid organs
and the blood and are CD62L+ CCR7+ cells. Effector
memory cells, TEM, are circulating CD62L
- CCR7- cells
surveying the blood and peripheral tissues. For a long period
of time, all memory T cells were categorized into these two
populations. However, since then groups studying memory
T cells found that a population of the effector memory
T cells were residing in the peripheral tissues and did not
reenter the circulation (17,32). This memory population was
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coined tissue-resident memory T cells (TRM) and have been
identified in various tissue since including lungs, liver, in-
testine, and female reproductive tract and is identified by a
high expression of CD69, and in many tissues also CD103
and CD49a (13,19,31,43).
The crucial role that TRM cells play in cellular immunity
against respiratory infections has become clear over the last
decade. Several decades ago, early work on lung airway
T cells unknowingly provided some of the first descriptions
of tissue-resident memory CD8 T cells and their impor-
tance for protective immunity to heterosubtypic influenza
challenge. One of these first studies by Christensen et al.
that investigated airway memory T cells found that a
single intraperitoneal priming regimen was inferior to an
intraperitoneal-prime and intranasal-boost regimen for pro-
tection against a heterosubtypic influenza challenge (8).
Although this defect was originally attributed to differences
in the number of circulating influenza-specific memory CD8
T cells between vaccination regimens, armed with current
knowledge it is likely that the lack of influenza-specific
memory CD8 T cells in the respiratory tract after intra-
peritoneal priming was also a major contributing factor
(35,41,47). Another early study provided the first evidence
of a CD69+ ‘‘resting’’ influenza-specific memory CD8 T cell
population in the airways that was highly prevalent on day
50 postinfection, but gradually disappeared over the next
3–4 months (30). It was not until the formal identification
of TRM that the correlation between the gradual loss of
influenza-specific memory CD8 T cells from the airways
observed by Marshall et al. (30), and the gradual decline
in protective cellular immunity to heterosubtypic influenza
infection, could be fully appreciated (27).
More recent studies have employed parabiosis and/or
intravital labeling techniques to greatly expand our knowl-
edge of the TRM population in the lung (1,21). Virus-specific
lung TRM are essential for heterosubtypic immunity against
influenza viruses, and the gradual decline in immunity over
time parallels a gradual loss in lung TRM (56). Lung TRM
can be divided into two distinct subsets based on their lo-
calization in the interstitium or the airways. These unique
microenvironments lead to different phenotypic and func-
tional traits of interstitial and airway TRM, but both subsets
contribute to antiviral immunity (36,58). Transcriptional
analysis of lung TRM showed these cells have a similar core
genetic signature to TRM in other peripheral tissues, such as
the skin, gut, and genital tract (23,29). However, unlike TRM
in other sites, the requirements for establishment of TRM in
the lung, and the longevity of these cells in the tissue, are
unique. Several reports have shown the generation of lung
TRM requires that activated effector T cells re-encounter
their specific antigen in the lung tissue (35,41,47). This has
important implications for vaccination strategies, as intra-
muscular (i.m.) or subcutaneous vaccines that fail to traffic
antigen to the lungs are unlikely to generate airway or in-
terstitial TRM in sufficient numbers for cellular immune
protection.
Another critical difference between TRM in the lungs
versus other tissues is the gradual decay of the TRM pool in
both the airways and the interstitium. Although the mech-
anisms driving this loss are not fully understood, lung TRM
showed increased apoptosis under steady-state conditions
compared to circulating TEM (44). In addition, airway TRM
were more prone to cell death than interstitial TRM due
to the limited nutrients available in the airway environ-
ment (Uddba¨ck et al, in preparation; and S. Hayward et al, in
preparation). Although these findings would suggest that
vaccines designed to generate lung TRM would offer only
transient protection, several reports have described mecha-
nisms that can improve the longevity of lung TRM. Repeated
boosting of virus-specific cells resulted in decreased apo-
ptosis and prolonged maintenance of lung TRM under
steady-state conditions (51). It has also been shown that lung
TRM preferentially reside in areas of tissue repair within the
lung, and a more natural pathogen exposure history may
generate or maintain these niches to support TRM persistence
(47). Developing a better understanding of the interplay
between lung TRM and their local environment will be es-
sential for developing strategies to improve their longevity.
Choosing a Target
Apart from understanding T cell memory populations
and how the cellular immunity will provide cross protec-
tion, it is crucial during vaccine design to select the right
targets for the immune response. Long-lasting influenza-
specific memory T cells have been found in peripheral blood
from human blood donors up to at least 13 years after the
influenza infection (52). These long-lived T cells were still
functional and produced interferon gamma (IFNc) upon
ex vivo stimulation. While all of the internal proteins of
influenza are highly conserved relative to the surface protein
HA and NA (42), not all will serve as good targets for
inducing an immune response. NP, polymerase acid (PA),
polymerase basic protein 1 (PB1), PB2, and matrix protein 1
(M1) have been researched as potential targets with varying
results.
NP is by far the most investigated target as the CD8+
T cell response to influenza A infections in both mice and
humans is primarily dominated by an NP-specific response
(2,55). High number of NP-specific T cells can be found in
spleen, mediastinal lymph node, airways, and lungs after a
cleared influenza infection in mice, which provides re-
searchers with a tool that at least in part is translatable to
a human response. As Christensen et al. (8) illustrated in
their article from 2000, this influenza specific population,
when boosted to sufficient numbers, can provide protection
against subsequent infection with heterosubtypic influenza
strains. For a vaccine, viral vectors have been a popular
approach used to induce a protective NP-specific response.
Adenovirus and modified vaccinia virus Ankara (MVA)
encoding the NP gene have both been successful at gener-
ating a NP-specific T cells response (15,49). The NP-
specific cells generated in these studies were capable of
protecting mice against both homosubtypic and hetero-
subtypic challenge, also in the absence of B cells. Due to the
compiling studies clearly demonstrating NP as a frontrunner
in the selection of relevant targets, NP will likely be in-
cluded in the case of future T cell inducing vaccine. How-
ever, T cells are not infallible and if the majority of the CD8
T cell response is directed toward a single epitope that is
mutated between influenza strains, T cells will fail to rec-
ognize and clear the virus (49). Still, the risk of this hap-
pening is much lower compared to when targeting HA and
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NA, as the NP gene is highly conserved between influenza A
strains. To some extent the high degree of conservation of
the internal proteins between influenza strains can be ex-
plained by functional constraint (4). Moreover, using
mathematical modeling and mapping CD8 T cell NP epi-
topes in humans, Li et al. illustrated that the conservation is
likely dependent on several aspects, including the fact that
polymorphism of the human major histocompatibility
complex-I gene restricts the advantage of a mutated strain to
only a fraction of the human population carrying the rele-
vant MHC-I alleles, and shows that other epitopes can
compensate when infection occurs with mutated variants of
the influenza virus (26). The possibility of escape variants of
the NP gene nevertheless stresses the need to investigate
other target genes as a way to increase the breadth of the
vaccine induced response and avoid immune escape.
In a 2017 study from our research group, the immune
response generated in response to vaccination with an ade-
noviral vector expressing PB1, a relatively poorly investi-
gated target, was analyzed (50). We found that by linking
the PB1 gene to invariant chain in a nonreplicating adeno-
virus (AdIiPB1) (18), vaccination induced high numbers of
CD8 memory T cells that produced cytokines including
IFNc in response to ex vivo stimulation with PB1703–711
peptide (3). However, despite the high number of PB1-
specific memory T cells in C57BL/6 mice, AdIiPB1 vacci-
nated subjects only displayed 50% survival upon lethal
challenge. The PB1-specific T cells generated showed low
cytolytic capacity in vivo and after further investigation we
found that the PB1703–711 peptide-MHC complex had low
stability over time, resulting in a very high concentration of
peptide being required for activation of the T cells. This
correlates with a previous study by Peter C. Doherty and
Stephen Turners group demonstrating the connection be-
tween peptide-MHC stability and CD8 T cell activation
(10). Despite evidence that intra nasal priming route could
improve the immunity to low avidity targets, also published
by Peter C. Doherty in collaboration with Katherine Ked-
zierskas group, protective capacities by the T cells generated
by AdIiPB1 vaccination in C57BL/6 mice was not sufficient
despite an intra nasal priming route (53). These results
emphasized that many factors apart from cell numbers need
to be considered when choosing a vaccine target. In addition
to this, AdIiPB1 was less efficient at inducing high number
of CD8 T cells in the lung and airways compared to ade-
noviruses expressing other genes such as NP and PA (Un-
published data). Further, a DNA vaccine expressing PB1
induced an immune response that could provide homo-
subtypic protection in Balb/C mice; however, cross-protective
capacities of the immunity generated were never investigated
(22). Interestingly though, PB1 epitopes were identified as
among the most prevalent in humans in a study from As-
sarsson et al. in 2008, and PB1 still has potential as a tar-
get, in particular if combined with other genes (2). Despite
generating a significant response in mice, few PA epitopes
are described in humans and PA has been poorly investigated
as a target for an influenza vaccine. Encoded by an adeno-
virus, immunization with PA can generate an immune re-
sponse and protect against influenza challenge in both
C57BL/6 and Balb/C mice (Article in preparation). The PA-
specific response observed in mice is not directly translatable
to humans; however, it can still be used to understand dif-
ferences in different antigen-specific responses. In addition,
to broaden protection and reduce chance of immune escape
by mutations, PA is of interest.
M1 epitopes have also been identified at high frequencies
in the human population and M1 has therefore been inves-
tigated as a vaccine target, both as a stand-alone but mainly
in combination with NP (7,28,45). One of the most suc-
cessful trials have been a heterologous prime boost strategy
where first immunization occurs with a chimpanzee ade-
novirus vector encoding NP+M1 fusion protein and a con-
served part of the HA stalk (cH13/14), followed by boosting
with a MVA vector encoding the same targets; using this
approach vaccination have shown promising results in mice
and ferrets (34). Importantly, the MVA vaccine both with
and without the addition of the AdNP+M1 has also been
well tolerated in humans and significantly increased num-
bers of circulating? Memory T cells (5,9). Notably, in these
studies the vaccines were administered i.m., the most
common administration route in humans. In one initial study
using the MVA+Ad vaccine regime in mice, an intranasal
route was used for boosting with Ad after i.m. priming with
MVA, and this induced higher number of antigen-specific
cells in the BAL of mice, compared to a i.m. + i.m. delivery
(24). However, localized cellular immunity in response to
the MVA+Ad vaccination regime has not been further im-
plemented or investigated down the line and, as will be
discussed below, it is likely that vaccination by the i.m.
route, though established and practical, will not result in the
most optimal protection possible.
Local Delivery
For a vaccine to generate the intended response, vacci-
nation route needs to be carefully considered. Vaccination
must not only deliver the vaccine in a safe manner for pa-
tients, but also be practical. Therefore, unnecessary painful
routes or complicated regimes must be carefully evaluated
before taken into use. As lung TRM cells are gaining in-
creased attention, and compiling studies illustrates their
importance for optimal cross protection in respiratory in-
fection (36,56), a lot of recent immunization strategies have
focused on the ability to induce a TRM population and how
to make this population stable over time. As previously
mentioned, the majority of data indicate that airway and
lung interstitium TRM cells require local antigen for estab-
lishment, which means that the vaccine need to be admin-
istered locally into the airways (46). Intranasal vaccination
with an AdNP have successfully generated an influenza-
specific CD8 T cells response in the lungs that was able
to provide cross protection against different influenza A
strains (20). However, it was never investigated how long
the induced immunity lasted as viral challenge was per-
formed 3 weeks after vaccination at the latest. Moreover,
virus-like particles including epitopes from HA and M1
have also been used in intranasal vaccination to generate
localized cross-reactive CD8 T cells, but again protection
has been poorly investigated beyond a few months post-
vaccination (14).
The live attenuated influenza virus (LAIV) FluMist, is the
only commercially available vaccine that is delivered lo-
cally into the airways in the form of a nose spray, demon-
strating that intranasal application is possible also in
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humans. Even though the primary goal of FluMist has been
to induce a B cell and antibody mediated immune response,
it has also been investigated as a way to increase CD8
T cells with promising results (16,57). In addition, a PR8
LAIV has been studied and when administered intranasally,
it has been found able to establish a CD8 T cell population
in the lungs of mice, which was crucial for clearance of a
heterosubtypic influenza challenge (54).
We showed, in 2016, that by immunizing with AdNP both
intranasally and subcutaneously we could induce long-
lasting immunity in mice (Fig. 1) (49). By combining the
two vaccination routes, both a strong localized and cen-
tral immune response was induced. The generated memory
T cell populations were cross protective and protection
lasted for at least 8 months. When the phenotype of the
airway population was analyzed, a substantial part of the
antigen-specific airway population expressed residency mark-
ers CD69 and CD103. Recently, we have been exploring the
underlying reasons for this long-lasting protection, and we
demonstrated that persistent antigen after adenovirus vacci-
nation can maintain a lung TRM population long term (Fig. 2)
(Article in preparation). Inflation, the concept that a small
amount of persistent antigen can stimulate a T cell popula-
tion without causing T cell exhaustion, has recently been
gaining substantial attention and also how inflation can
maintain the TRM population in the lungs and airways (6).
Except for adenovectors, intranasal vaccination with Murin
Cytomegalovirus (MCMV) vectors has recently been ex-
plored as a method for generating and maintaining a TRM
population by inflation long term (37,38,59). However, as
discussed earlier, cells in the lung and particularly the air-
ways have a high rate of apoptosis and the time limit of the
inflation process and the effect on the TRM population long
term in the lungs has not been thoroughly studied. If and
when the persistent antigen in the lungs is cleared, unless the
population has permanently differentiated, the antigen-
specific TRM cells will likely be lost within months. How-
ever, it has been suggested that, using a doxycycline-
regulated adenovirus, the majority of programming occurs
early after priming and if the antigen is removed later than
60 days after priming it has little or no effect on the memory
population (11).
Moving Forward
To obtain heterosubtypic immunity against influenza in-
fections, memory T cells are highly likely to play an im-
portant role. T cell immunity will, however, not provide
sterile immunity and to provide optimal protection, a
FIG. 1. The adenovirus as a vaccine vector. (A) Illustration of an adenovirus vector and the dual immunization strategy.
(B) Representative illustration of TRM population dynamics over time after influenza infection and AdNP immunization.
CMV; cytomegalovirus promotor; i.n. intranasal; s.c. subcutaneous; TRM, tissue-resident memory T cells.
FIG. 2. Mechanisms of how persistent antigen may maintain a lung TRM population TRM population dynamics in the lung
of i.n.+s.c. AdNP immunized mice. Persistent antigen (represented by the APC) in the lungs after AdNP immunization may
maintain the population through differentiation of circulating TEM cells surveying the peripheral tissue (left), by antigen-
driven proliferation (middle), or by prevention of apoptosis (right), or by any combination of these possibilities. APC,
antigen-presenting cells.
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vaccine likely also has to induce an antibody response.
Several studies have been investigating a combination of T
and B cell targets, with the MVA vector currently coming
out as the frontrunner. One of the greatest challenges with a
CD8 T cell inducing influenza vaccine is how to maintain a
large enough CD8 T cells population in the respiratory
system to have long-lasting protection. As discussed earlier,
the antigen-specific population located in the airways is
under particular stress, causing them to undergo apoptosis at
a high rate. Several studies point to the importance of local
antigen for the formation and maintenance of TRM and it is
possible that extended exposure by persistent antigen or
repeated antigen exposure can increase the survival of the
TRM population (51). It is reasonable to hypothesize that
repeated antigen exposure and persistent antigen cause a
similar result, namely an extended life span of the TRM
population. How long the TRM population can be maintained
in the lungs of humans still remains to be investigated and
there is currently no solution to the high apoptosis rate of
TRM population. One issue of translating mouse studies to
humans is that most of murine studies are performed in mice
with no pre-existing immunological memory toward influ-
enza, and vaccination is usually not followed by any irrel-
evant infections. Both these scenarios are likely to occur in
humans and to influence the formation and maintenance of
the human lung TRM population and therefore needs to be
further investigated.
Methods to improve the TRM population by increasing the
size, extending the life span and thereby heterosubtypic
immunity has been explored by including adjuvant genes
important for resident memory T cell formation and survival
in the vaccines (25,39). However, these approaches have
used self-molecules, 4-1BB and interleukin-1b, and the
adverse effects needs to be carefully evaluated. Moreover, if
the high apoptosis rate of the lung TRM population observed
in multiple studies cannot be prevented, no matter how large
a population we start out with, eventually the cells, and
heterosubtypic protection, will be lost. Either scientist need
to figure out a way to make the airway environment less
stressful for the cells and reduce apoptosis, an unlikely
scenario as this could affect other basic or immunological
functions in the lung, or the TRM population needs to be
replenished based on persistent antigen that can pull circu-
lating TEM into the TRM population. If neither of these op-
tions will be possible, perhaps a universal one-time
influenza vaccine is too much to ask for?
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